Thursday's After-Hours Movers: Earnings Shaking LinkedIn, Expedia, EA, Amgen & Boston Beer Co
Shares of LinkedIn Corp (NYSE: LNKD) were up about 8 percent at time of publication. The company reported earnings of $0.55 per share on revenue of $711.74 million, doubling its guidance, which called for earnings of $0.28 per share on sales of $672.5 million.
The results also beat the Street’s consensus estimate, which pointed towards earnings of $0.32 per share on sales of $681.56.
Also surging on its earnings report is Expedia Inc (NASDAQ: EXPE), which rose about 6.5 percent after the bell rang. The online travel company issued earnings of $0.89 per share on revenue of $1.66 billion, up 11 percent year-over-year. Analysts were modeling consensus earnings of $0.85 per share on sales of $1.661 billion.
On the other hand, shares of Electronic Arts Inc. (NASDAQ: EA) were down more than 3 percent. Earnings came in at $0.15 per share, and sales at $693 million. Experts were projecting earnings of $0.04 per share on revenue of $674.33 million, while management had guided earnings of $0.00 per share on sales of $640 million.
Nonetheless, the stock is tumbling on weak guidance. The company is expecting adjusted EPS of $2.85 and revenue of $4.3 billion for 2016, versus analysts’ estimate of $2.80 per share and $4.8 billion.
Amgen, Inc. (NASDAQ: AMGN) was up almost 2 percent after hours following another earnings beat. The biotech company delivered EPS of $2.57 on revenue of $5.37 billion, above the Street’s consensus of $2.43 and $5.32 billion. In addition, management boosted its full-year guidance, which now calls for EPS of $9.55 to $9.80, up from $9.35 to $9.65, and revenue between $21.1 billion and $21.4 billion, up from $20.9 billion to $21.3 billion.
Finally, Boston Beer Co Inc (NYSE: SAM) was trading up almost 3 percent after the bell. The U.S. brewer reported EPS of $2.18 on revenue of $252.2 million, versus experts’ expectations for EPS of $1.83 on sales of $248.8.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.